The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a two-year randomised trial and the Extension study was a 24-week two-arm extension study in the United States in which patients received either brolucizumab 6mg or aflibercept 2mg. The efficacy at the end of the core study was maintained during the extension study both in terms of best corrected visual acuity and central macular thickness. There was also no difference in ocular and non-ocular safety profiles. The authors conclude that the safety and efficacy with the intended commercial formulation of brolucizumab 6mg in nAMD patients was consistent with that observed in the HAWK and HARRIER studies.
Brolucizumab in age-related macular degeneration, HAWK Study
Reviewed by Kurt Spiteri Cornish
HAWK extension study: safety and efficacy of intravitreal brolucizumab in neovascular age-related macular degeneration.
CONTRIBUTOR
Kurt Spiteri Cornish
Sheffield Teaching Hospitals NHS Trust, London, UK.
View Full Profile
